https://orcid.org/0000-0003-3680-9066
References
- RosskampR, Wernicke-PantenK, DraegerE. Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract. 1996;31(Suppl):S33–S42. doi:10.1016/0168-8227(96)01228-48864639
- ZhangH. ADRs of oral hypoglycemic drugs. Tianjin Pharm. 2017;29(2):75–82.
- American Diabetes Association. Standards of Medical Care in Diabetes—2020 Abridgedfor Primary Care Providers. Clinical Diabetes. 2020;38(1):10–38. doi:10.2337/cd20-as01 https://clinical.diabetesjournals.org/content/diaclin/38/1/10.full.pdf.
- The Japan Diabetes Society. Available from: Treatment guide for diabetes 2016–2017. http://www.fa.kyorin.co.jp/jds/uploads/Treatment_Guide_for_Diabetes_2016-2017.pdf. Accessed 618, 2020.
- Chinese Diabetes Society. Guidelines for the prevention and treatment of type 2 diabetes in China 2010. Available from: http://www.diab.net.cn/UploadFile/Ueditor/file/20160811/6360650768334000005174021.pdf. Accessed 618, 2020.
- Hoechst Roussel Pharmaceuticals Amaryl® (Glimepiride Tab- Lets) 1, 2, and 4 Mg. Kansas City: Hoechst-Roussel Pharmaceuticals; 2001.
- Amaryl (glimepiride tablets). Bridgewater, NJ: Sanofi-Aventis US LLC; 2018 Available from: http://products.sanofi.us/Amaryl/Amaryl.pdf.
- MalerczykV, BadianM, KornA, LehrKH, WaldhauslW. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metabol Drug Interact. 1994;11(4):341–357. doi:10.1515/DMDI.1994.11.4.34112369757
- RosenkranzB. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996;28(9):434–439. doi:10.1055/s-2007-9798338911979
- SuzukiK, YanagawaT, ShibasakiT, KaniwaN, HasegawaR, TohkinM. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006;72(2):148–154. doi:10.1016/j.diabres.2005.09.01916325295
- WangR, ChenK, WenSY, LiJ, WangSQ. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther. 2005;78(1):90–92. doi:10.1016/j.clpt.2005.03.00816003298
- BadianM, KornA, LehrKH, MalerczykV, WaldhauslW. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact. 1996;13(1):69–85. doi:10.1515/DMDI.1996.13.1.698902432
- BorgesNC, Taveira YdelA, MazucheliJA, et al. Comparison study of two glimepiride formulations bioavailability in healthy volunteers of both sexes after a single dose administration. Arq Bras Endocrinol Metabol. 2007;51:950–955. doi:10.1590/S0004-2730200700060000917934662
- MatsukiM, MatsudaM, KoharaK, et al. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once-versus twice-daily dosing. Endocr J. 2007;54:571–576. doi:10.1507/endocrj.K06-05217603225
- LeiT, Yi-lingH, LuH, et al. Pharmacokinetic studies of glimepiride and its hydroxyl-metabolite in healthy volunteers. Chin J Clin Pharmacol Ther. 2006;11:868–972.
- LiuY, ZhangMQ, ZhuJM, et al. Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Clin Ther. 2010;32(5):986–995. doi:10.1016/j.clinthera.2010.04.01620685507
- World Medica lAssociation (WMA) Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 618, 2020.
- European Agency for the Evaluation of Medicinal Products (EMEA). ICH E6 (R2) guideline for good clinical practice; 2016 Available from: https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice#current-version—revision-2-section. Accessed 618, 2020.
- National Medical Products Administration. Guideline for good clinical practice. Available from: http://www.nmpa.gov.cn/WS04/CL2101/329583.html. Accessed 618, 2020.
- National Medical Products Administration. Center for Drug Evaluation. Guideline for bioavailability and bioequivalence studies of generic drug products. Available from: http://www.nmpa.gov.cn/WS04/CL2093/331454.html. Accessed 618, 2020.
- XuH, MurrayM, McLachlanAJ. Influence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs. Curr Drug Metab. 2009;10(6):643–658. doi:10.2174/13892000978937538819799532
- Food and Drug Administration. Guidance on Glimepiride. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Glimepiride_tab_20496_RC11-04.pdf. Accessed 618, 2020.
- JovanovicD, StojsicD, ZlatkovicM, Jovic-StosicJ, JovanovicM. Bioequivalence assessment of the two brands of glimepiride tablets. Vojnosanit Pregl. 2006;63(12):1015–1020. doi:10.2298/VSP0612015J17252706